Skip to main content
. 2013 Dec;51(12):4266–4269. doi: 10.1128/JCM.02411-13

Table 1.

Evolution of the CMV PCR and genotypic resistance tests in blood and cerebrospinal fluid samplesa

Date(s) Blood result
 Cerebrospinal fluid result
 Antiviral treatment
CMV PCRb Amino acid change associated with CMV resistance to antiviral drugsf
 CMV PCRb Amino acid change associated with CMV resistance to antiviral drugs
 Drug(s) Duration
Date UL97 PTc UL54 DPd Date UL97 PTc UL54 DPd
July 2008–June 2009 − − Oral ACV 11 mos
June 2009 + (3.9 → <2.7) − GCV 2 wks
June–July 2009 − Oral ACV 4 wks
July–August 2009 + (3.2 → 5.4) FOS 3 wks
August–September 2009 + (5.4 → 3.9) FOS + GCV 3 wks
September–December 2009 + (3.9 → 3.6) November 2009 0 0 CDV + GCV 14 wks
December 2009 + (3.6 → 5.8) FOS + GCV 2 wks
December 2009–January 2010 + (5.8 → <2.7) FOS + GCV + artesunate 4 wks
January–March 2010 − VGCV 2 mos
March–April 2010 + (2.9 → 4.4) VGCV 2 mos
May 2010 + (4.4 → <2.7) May 2010 M460I L545S FOS + GCV 2 wks
June 2010–January 2011 − VGCV 7 mos
January 2011 + (3.3 → <2.7) January 2011 0 0 FOS 2 wks
January–September 2011 − VACV 9 mos
September–October 2011 − + (3.8 → 3.9) September 2011 H520Q L545S FOS + GCV 5 wks
October–November 2011 − + (3.9 → 4.9) VACV 9 wks
November 2011–June 2012 + (3.4 → 3.7) February 2012e 0 0 + (4.9 → 4.3) February 2012 H520Q L545S VACV 7 mos
February 2012e H520Q L545S
May 2012 M460I L545S
June–August 2012 (death) + (3.7 → 5.3) June 2012 M460I L545S + (4.3 → 3.2) FOS + GCV 5 wks
a

CMV, cytomegalovirus; UL97 PT, UL97 phosphotransferase; UL54 DP, UL54 DNA polymerase; ACV, acyclovir; GCV, intravenous ganciclovir; FOS, foscarnet; CDV, cidofovir; VGCV, valganciclovir; VACV, valaciclovir; i.v., intravenous.

b

In cases of positive CMV PCR results, results of the PCR at the initiation and at the end of each antiviral regimen are indicated in parentheses (expressed in log10 copy numbers/ml).

c

In all genotypic resistance tests, the following amino acid changes relative to natural polymorphisms of CMV UL97 phosphotransferase were isolated: Q19E, N68D, S108N, and I244V.

d

In all genotypic resistance tests, the following amino acid changes relative to the natural polymorphism of CMV UL54 DNA polymerase were isolated: A885T and N898D.

e

Genotypic resistance tests were performed using the same blood sample (the second test has been retrospectively assessed).

f

A “0” entry indicates that no amino acid change was evidenced.